EPFL researchers uncover a notorious cholera strain that contains sophisticated immune systems to fend off viruses, which ...

New research demonstrates how specially engineered bacteria taken orally can operate as a delivery system for vaccines and antiviral therapies.

Armata Pharmaceuticals ARMP shares have skyrocketed 72.3% in the past month. The massive surge in the stock price was ...

Armata Pharma reports positive data from phase 1b/2a diSArm study of intravenously administered AP-SA02 to treat S. aureus bacteremia: Los Angeles Tuesday, May 20, 2025, 17:00 Hrs ...

Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) ...

Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage ...

Operator: Greetings and welcome to the BiomX First Quarter 2025 Financial Results Conference Call. At this time, all ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...